 MELBOURNE, Australia, Aug. 09, 2021 GLOBE NEWSWIRE -- Opthea Limited ASX:OPT; Nasdaq:OPT, a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that recruitment is open to patients in Canada for the Phase 3 pivotal clinical program of OPT-302 for the treatment of wet neovascular age-related macular degeneration AMD. Following formal authorization from the regulatory agency Health Canada, patient enrollment in the two concurrent Phase 3 registrational clinical trials, ShORe Study of OPT-302 in combination with Ranibizumab and COAST Combination OPT-302 with Aflibercept Study can now begin in Canada. The goal of the two studies is to evaluate the benefits of the Companys VEGF-CD trap inhibitor, OPT-302, for wet AMD in treatment-naïve patients. 